The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy

Artif Cells Nanomed Biotechnol. 2016 Jun;44(4):1051-61. doi: 10.3109/21691401.2014.998830. Epub 2015 Jan 23.

Abstract

Cancer is one of the most important causes of death all over the world, which has not yet been treated efficiently. Although several therapeutic approaches have been used, some side effects such as toxicity and drug resistance have been observed in patients, particularly with chemotherapy. The nanoparticle-mediated drug delivery systems (DDS) have a great potential to improve cancer treatment by transferring therapeutic factors directly to the tumor site. Such a treatment significantly decreases the adverse effects associated with cancer therapy on healthy tissues. Two main strategies, including passive and active methods, have been considered to be effective techniques which can target the drugs to the tumor sites. The current review sheds some light on the place of nanotechnology in cancer drug delivery, and introduces nanomaterials and their specific characteristics that can be used in tumor therapy. Moreover, passive and active targeting approaches focus on antibodies, particularly single chain variable fragments (scFv), as a novel and important ligand in a drug delivery system.

Keywords: cancer therapy; drug delivery; nanoparticle; scFv; tumor targeting.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use*
  • Drug Delivery Systems / methods*
  • Humans
  • Immunotherapy / methods*
  • Nanoparticles / chemistry*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Single-Chain Antibodies / immunology
  • Single-Chain Antibodies / therapeutic use*

Substances

  • Antibodies, Neoplasm
  • Single-Chain Antibodies